Table 1.
RA participant characteristics. Data are presented as mean (SD) or median (IQR) unless otherwise specified.
| Characteristics | All Subjects |
|---|---|
| n | 50 |
| Age, yrs | 51.2 (13.3) |
| Female, n (%) | 39 (78) |
| Black, n (%) | 18 (36) |
| BMI, kg/m2 | 30.1 (8.5) |
| Obese, BMI ≥ 28 kg/m2, n (%) | 30 (60) |
| ALMI, kg/m2 | 7.5 (1.30) |
| ALMI Z score | −0.24 (1.05) |
| LBMI, kg/m2 | 17.3 (2.5) |
| LBMI Z score | −0.22 (1.07) |
| FMI, kg/m2 | 12.4 (5.6) |
| FMI Z score | 0.09 (1.20) |
| pQCT muscle CSA, cm2 | 64.4 (12.5) |
| Tibia-adjusted muscle CSA Z score | −0.42 (1.23) |
| pQCT fat CSA, cm2 | 32.7 (14.9) |
| Tibia-adjusted fat CSA Z score | 0.36 (1.13) |
| Muscle density, mg/cm3 | 73.3 (71.0, 75.0) |
| Muscle density Z score | −0.58 (0.82) |
| DAS28-CRP | 3.14 (1.17) |
| HAQ score | 0.775 (0.15–1.45) |
| CCP-positive, n (%) | 38 (76) |
| Disease duration, yrs | 10 (4–19) |
| SvdH score | 21 (2–53) |
| CRP, mg/dl | 0.5 (0.5–1.3) |
| TNF-α, pmol/l | 1.12 (0.83–4.89) |
| Adiponectin, ng/ml | 7790 (5430–12,230) |
| IGF-1, ng/ml | 138.5 (48.4) |
| Medications, n (%) | |
| Current MTX | 32 (64) |
| Current biologic therapy | 32 (64) |
| Current prednisone | 20 (40) |
| Ever MTX | 41 (87) |
| Ever biologic therapy | 38 (76) |
| Ever prednisone | 40 (80) |
RA: rheumatoid arthritis; IQR: interquartile range; BMI: body mass index; ALMI: appendicular lean mass index; LBMI: lean body mass index; FMI: fat mass index; pQCT: peripheral quantitative computed tomography; CSA: cross-sectional area; DAS28: Disease Activity Score in 28 joints; CRP: C-reactive protein; HAQ: Health Assessment Questionnaire; CCP: cyclic citrullinated peptide antibody; SvdH: Sharp/van der Heijde method; TNF-α: tumor necrosis factor-1; IGF-1: insulin-like growth factor 1; MTX: methotrexate.